ABSTRACT NMR was used to investigate the reaction of cis-and trans-[RuC12(DMSO)4] with the antiviral drug acyclovir, a guanine derivative containing the acyclic (2-hydroxo)ethoxymethyl pendant linked to N(9). Studies were performed in aqueous solutions at ambient temperature and at 37 o C, and at various molar ratios. Both isomers yielded two compounds, a monoadduct and a bisadduct, the relative yields being dependent upon the metal to ligand concentration ratios. The products derived from the two Ru isomers displayed identical NMR spectra, suggesting that they have the same coordination environment, however the rate of formation of the monoadduct was higher in the case of the trans isomer than in the case of the cis isomer, while the rate of conversion of the monoadduct into the bisadduct appeared to be similar in both cases. As a consequence in the case of the trans isomer there is accumulation of monoadduct in the early stage of the reaction, whose concentration afterwards decreases with the progress of the reaction. As for platinum, also for ruthenium the preferred binding site s N(7) of the purine base, however, in the case of ruthenium a discrete amount of bisadduct is formed even in the presence of an excess of metallic substrate with respect to the acyclovir ligand; under similar conditions a platinum substrate would have given, nearly exclusively, the monoadduct.
INTRODUCTION
Cisplatin, cis-[PtClz(NH)], is one of the most widely used drugs in cancer therapy 1 ], however the appearance of severe side-effects, the drug resistance which develops after a prolonged treatment, and the limited spectrum of activity has led scientists to search for new antcancer metal based drugs. Ruthenium complexes are among those which have displayed a great potential for medical applications. In particular cis-and trans-[RuClz(DMSO)4], two neutral octahedral Ru(II) compounds, possess significant antitumor activity and a remarkable antimetastatic activity in some murme tumor models [2] [3] [4] . The cis isomer has one O-bonded and three facial S-bonded DMSO molecules, while in the trans isomer, all four DMSO molecules are S-bonded. The trans isomer is markedly more toxic and reactive than the cis isomer [3, 5, 6] . In vivo and in vitro experiments showed that both isomers interact with DNA [7, 8] and preferential interaction with adjacent guanines was found upon treatment with pBR 322 DNA [9] . As for the platinum complexes, also for ruthenium the target atom of the guanine base appears to be N(7). Apart from the abo.ve mentioned compounds, also other ruthenium compounds have proved to be acuve antitumor drugs and one of them, NAMI-A, has entered clinical trials as an antimetastatic agent 10] .
In previous papers we investigated the reaction of platinum compounds with the antiviral drug acyclovir [11] [12] [13] ; a guanosine analog characterized by having an acyclic residue [a (2-hydroxy)ethoxymethyl group] linked to N (9) . The scope was that of synthesizing multifunctional drugs in which either the anticancer activity of the platinum moiety, or the antiviral activity of the acyclovir residue could be enhanced. In some occasions interesting results, particularly regarding the antitumor activity, were obtained [14, A similar investigation has now been performed on two ruthenium substrates and the results are reported herein.
MATERIALS AND METHODS
Cis-and trans-[RuC12(DMSO)4] were synthesized and recrystallized as previously retorted [5.16] . Acyclovir (Sigma) was used with no further purification. The Fig. 1 Using an acyclovir to trans-[RuC12(DMSO)4] molar ratio of 2:1, the same products, compounds I and II, observed in the previous experiment are formed. However the time profile of the product formation ( Fig. l b) differs from that observed when using the reactants in a 1:1 molar ratio. The concentration of complex I again increases during the first 30 minutes, and then it starts decreasing. Complex II becomes the dominant species after 90 minutes (ca. 45%)and increases to ca. 70% of the overall reaction products after 4 hours. The solution reaches a steady composition within 24 h. Free acyclovir (8.5%) is present in the final reaction mixture in which 83% of total ACV is present as compound II, and 8.5% as compound I. All the trans-Ru substrate has been consumed by the end of the reaction.
The reaction progress observed using, a slight excess of the ruthenium substrate (ACV:trans-Ru r 1:1,25) was very similar to that of r (Fig. c) . However under these conditions the monoadduct remains the dominant species even at the end of the reaction (after 1 day). This seems reasonable since the ligand concentration is now even smaller than that of the Ru substrate. It is also worth noting that the percentage of bisadduct is still significantly high notwithstanding the excess of metallic substrate over the acyclovir ligand.
The reaction of acyclovir with trans-Ru has also been performed at 37 C ( Figure 2 ). It proceeds much faster (ca 10 times) than the corresponding reaction carried out at ambient temperature but the ratio of the products at the end of the reaction is similar.
In all the _experiments performed with trans-Ru the final spectra exhibit two single resonances at i5 (Fig. 3) . In the same region (5.57 ppm) the H(I') atoms of the bisadduct appear as an AB quartet indicating that the C(I')H2 protons are not equivalent but undergo a diastereotopic splitting of ca. 0.1 ppm. The non-equivalence of the C(1 ')Hz protons is characteristic ofa bisadduct with the two ACV ligands in cis positions and can originate from a restricted rotation of the alkyl chain about the C(I')-N(9) bond and of the two coordinated acyclovir molecules about the N(7)-Ru bonds. The H(2') and H(3') protons also appear as a singlet in the monoadduct and as multiplets in the bisadduct.
The DMSO methyl signals partially overlap with the H(2') and H (3 ) confirms the formation of Ru-N(7) bonds. Negligible shifts were observed for the alkyl chain carbons, C(I'), C(2') and C(3'), confirming the non involvement in the metal coordination of either the ether oxygen or the hydroxyl group. Table II" Fig. 4 . Two products are formed also in this case, they exhibit H NMR spectra identical to those of the compounds obtained in the previous reaction of the trans-Ru isomer with ACV. performed in water solution at room temperature. The concentrations were determined by integration of the peak areas of the aromatic region (H8 of ACV) in the H NMR spectra.
The kinetic profiles observed in the reactions of cis-Ru with acyclovir differ from those observed for the trans-Ru isomer. When the reactions are carried on at room temperature the solution reaches a steady composition after 40 50 hour reaction time. In all cases the bisadduct is the compound that dominates after the first hour of reaction. The concentration of the monoadduct increases during the first 5 hours reaching about 20% of the overall ACV species present in solution. At the end of the reaction the bisadduct accounts for about 70% of the total for r 1"1 or 1"1.25, while at a molar ratio of 2:1 it 0 reaches about 80 of the total ACV species.
The reaction of acyclovir with cis-Ru has also been recorded at 37 C for r 1 and 2.
The rates are much faster (ca. 10 times) but the type and concentration f products are the same as those observed at ambient temperature.
It is worth noting that in all the reactions performed with the cis-Ru complex, the concentration of complex I in the initial stage of the reaction never increases above that at the end of the reaction, contrary to what has been observed in all reactions performed with trans-Ru (Fig. 1 a-1 c) where the concentration of complex I reaches a maximum in the early stage of the reaction and then decreases.
As mentioned earlier, the 1H NMR spectra of the two reaction products, (compounds I and II) obtained in the reaction of acyclovir with cis-Ru are exactly the same as those obtained in the reaction of acyclovir with trans-Ru. However, during the progress of the reaction, the DMSO methyl region is different, reflecting the different hydrolysis products of cis-Ru as compared to those of trans-Ru [5, 16] . Fig. 5 reports the reaction progress in the case of ambient temperature and using a slight excess of metal substrate (r 1"1.25). In the reaction of cis-Ru with 5'-GMP [29] , the 8uanine N (7) 
CONCLUSIONS
The present investigation, apart from confirming the analogy in the coordination behavior of acyclovir with respect to other guanine bases, has also underlined some substantial differences between the behavior of antitumoral platinum(II) and ruthenium(II) complexes. These differences are: i) Greaterpropensity of the ruthenium(II) complexes to give the bis-adducts as compared to monoadducts. Under similar experimental conditions (e. g. use of an excess of metal substrate with respect to the purine ligand) platinum(II) substrates would have given, almost exclusively, the monoadduct, ii) Analogy in the behavior of the cis and the trans isomers of the ruthenium(II) complex which give exactly the same mono and bisadducts independently from the different coordination geometry of the starting substrate. This is not the case of platinum(II) species which give different reaction products depending upon the cis or trans geometry of the starting substrate. These results may be relevant to the different antitumor activity of platinum and the ruthenium substrates.
Although giving similar products, the rate of formation of the monoadduct is higher in the case of the trans-Ru complex as compared to that of the cis-Ru isomer. This might imply that in both cases the reactive species is the diaqua complex. This would aso account for the greater propensity of the ruthenium substrates to give the bisadduct as compared to the platinum substrates.
An investigation of the antiviral and antitumoral activities of the ruthenium adducts with acyclovir (both the mono and the bis derivatives) is under way. It will be interesting tq compare the results with those already obtained for the antiviral and anticancer activity of the platinum complexes with acyclovir.
